CoChat

Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease

Open access
Schmidt, Amand F., Hunt, Nicholas B., Gordillo-Marañón, Maria, Charoen, Pimphen, Drenos, Fotios, Kivimaki, Mika, Lawlor, Deborah A., Giambartolomei, Claudia, Papacosta, Olia, Chaturvedi, Nishi, Bis, Joshua C., O’Donnell, Christopher J., Wannamethee, Goya, Wong, Andrew, Price, Jackie F., Hughes, Alun D., Gaunt, Tom R., Franceschini, Nora, Mook-Kanamori, Dennis O., Zwierzyna, Magdalena, Sofat, Reecha, Hingorani, Aroon D., Finan, Chris · 2021 · Nature Communications
Cited by 142

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Development of cholesteryl ester transfer protein (CETP) inhibitors for coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and drug target Mendelian randomization of CETP protein concentration, comparing this to Mendelian randomization of proprotein convertase subtilisin/kexin type 9 (PCSK9). We show that previous failures of CETP inhibitors are likely compound related, as illustrated by significant degrees of between-compound heterogeneity in effects on lipids, blood pressure, and clinical outcomes observed in trials. On-target CETP inhibition, assessed through Mendelian randomization, is expected to reduce the risk of CHD, heart failure, diabetes, and chronic kidney disease, while increasing the risk of age-related macular degeneration. In contrast, lower PCSK9 concentration is anticipated to decrease the risk of CHD, heart failure, atrial fibrillation, chronic kidney disease, multiple sclerosis, and stroke, while potentially increasing the risk of Alzheimer’s disease and asthma. Due to distinct effects on lipoprotein metabolite profiles, joint inhibition of CETP and PCSK9 may provide added benefit. In conclusion, we provide genetic evidence that CETP is an effective target for CHD prevention but with a potential on-target adverse effect on age-related macular degeneration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-25703-3

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 142

Metadata

Authors
Schmidt, A. F., Hunt, N. B., Gordillo-Marañón, M., Charoen, P., Drenos, F., Kivimaki, M., Lawlor, D. A., Giambartolomei, C., Papacosta, O., Chaturvedi, N., Bis, J. C., O’Donnell, C. J., Wannamethee, G., Wong, A., Price, J. F., Hughes, A. D., Gaunt, T. R., Franceschini, N., Mook-Kanamori, D. O., Zwierzyna, M., Sofat, R., Hingorani, A. D., & Finan, C.
Venue
Nature Communications
Published
2021-09-24
Volume
12
Issue
1
Pages
5640-5640
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3087544811
Cited by
142
References
30
FWCI
20.12
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. https://app.cochat.ai/papers/10.1038/s41467-021-25703-3
The paper
Schmidt, A. F., Hunt, N. B., Gordillo-Marañón, M., Charoen, P., Drenos, F., Kivimaki, M., Lawlor, D. A., Giambartolomei, C., Papacosta, O., Chaturvedi, N., Bis, J. C., O’Donnell, C. J., Wannamethee, G., Wong, A., Price, J. F., Hughes, A. D., Gaunt, T. R., Franceschini, N., Mook-Kanamori, D. O., . . . Finan, C. (2021). Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature Communications. https://doi.org/10.1038/s41467-021-25703-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.